Compare Recursion Pharmaceuticals Inc (RXRX) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $211.1 (market cap $39.48B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 22.7× Recursion Pharmaceuticals Inc's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | TTWO | |
|---|---|---|
Market Cap | $1.74B | $39.48B |
Sector | Health | Media |
52-Week High | $6.79 | $262.29 |
52-Week Low | $2.84 | $189.69 |
Enterprise Value | $1.26B | $40.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Take-Two Interactive (TTWO) trades at $213.29, down 0.65% on the day, amid bearish technical signals but strong analyst optimism driven by the upcoming Grand Theft Auto VI launch. The stock shows negative profitability with a net income margin of -4.79% and elevated valuation ratios, yet revenue growth to $5.63 billion in 2025 and recent earnings beats highlight operational resilience. Cash flow trends are volatile, with 2025 net cash flow positive at $457 million due to financing activities, while debt-to-asset ratio rose to 39.87%.
The outlook hinges on GTA VI's success, with a consensus price target of $302.60 implying significant upside. Risks include execution missteps, competitive pressures, and high debt, but institutional buying and no sell ratings reflect confidence in the long-term franchise value. Near-term volatility is expected around product launches and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
